| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A further look at the Cochran-Mantel-Haenszel risk difference
|
Sato, Tosiya
|
|
1995
|
16 |
5 |
p. 359-361
3 p.
|
artikel
|
| 2 |
Announcements
|
|
|
1995
|
16 |
5 |
p. 363-364
2 p.
|
artikel
|
| 3 |
Commentary regarding “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — the perspective of NIH clinical trialists”
|
Piantadosi, Steven
|
|
1995
|
16 |
5 |
p. 307-309
3 p.
|
artikel
|
| 4 |
Comments on NIH clinical trials valid analysis requirement
|
Meinert, Curtis L.
|
|
1995
|
16 |
5 |
p. 304-306
3 p.
|
artikel
|
| 5 |
Conventional null hypothesis testing in active control equivalence studies
|
Ng, Tie-Hua
|
|
1995
|
16 |
5 |
p. 356-358
3 p.
|
artikel
|
| 6 |
Discussion of “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists”
|
Woolson, Robert F.
|
|
1995
|
16 |
5 |
p. 301-303
3 p.
|
artikel
|
| 7 |
Dose-ranging trials: Guidelines for data collection and standardized descriptions
|
Boissel, Jean-Pierre
|
|
1995
|
16 |
5 |
p. 319-330
12 p.
|
artikel
|
| 8 |
Impact of the NIH inclusion Guidelines
|
Baldwin, Wendy
|
|
1995
|
16 |
5 |
p. 300-
1 p.
|
artikel
|
| 9 |
Inclusion of women and minorities in clinical trials
|
Gore, Sheila M.
|
|
1995
|
16 |
5 |
p. 290-292
3 p.
|
artikel
|
| 10 |
Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists
|
Freedman, Laurence S.
|
|
1995
|
16 |
5 |
p. 277-285
9 p.
|
artikel
|
| 11 |
Prime time for Bayes
|
Kadane, Joseph B.
|
|
1995
|
16 |
5 |
p. 313-318
6 p.
|
artikel
|
| 12 |
Problems and suggested solutions in creating an archive of clinical trials data to permit later meta-analysis: An example of methotrexate trials in rheumatoid arthritis
|
Chernoff, Miriam C.
|
|
1995
|
16 |
5 |
p. 342-355
14 p.
|
artikel
|
| 13 |
Response to discussants' letters
|
Freedman, Laurence S.
|
|
1995
|
16 |
5 |
p. 310-312
3 p.
|
artikel
|
| 14 |
Response to “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists”
|
Bourassa, Martial G.
|
|
1995
|
16 |
5 |
p. 289-
1 p.
|
artikel
|
| 15 |
Response to “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists”
|
Boissel, Jean-Pierre
|
|
1995
|
16 |
5 |
p. 286-288
3 p.
|
artikel
|
| 16 |
Response to “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists”
|
Fraser, William D.
|
|
1995
|
16 |
5 |
p. 299-
1 p.
|
artikel
|
| 17 |
Response to “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists”
|
Buist, A.Sonia
|
|
1995
|
16 |
5 |
p. 296-298
3 p.
|
artikel
|
| 18 |
Response to “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists”
|
Brawley, Otis W.
|
|
1995
|
16 |
5 |
p. 293-295
3 p.
|
artikel
|
| 19 |
Use of cumulative meta-analysis in the design, monitoring, and final analysis of a clinical trial: A case study
|
Henderson, William G.
|
|
1995
|
16 |
5 |
p. 331-341
11 p.
|
artikel
|
Tijdschrift beschrijving